DE60025808D1 - Verwendung von protein thank, ein tnf homolog, zur hemmung des tumorwachstums - Google Patents

Verwendung von protein thank, ein tnf homolog, zur hemmung des tumorwachstums

Info

Publication number
DE60025808D1
DE60025808D1 DE60025808T DE60025808T DE60025808D1 DE 60025808 D1 DE60025808 D1 DE 60025808D1 DE 60025808 T DE60025808 T DE 60025808T DE 60025808 T DE60025808 T DE 60025808T DE 60025808 D1 DE60025808 D1 DE 60025808D1
Authority
DE
Germany
Prior art keywords
thank
homolog
tnf
protein
tumor growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60025808T
Other languages
English (en)
Inventor
B Aggarwal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Application granted granted Critical
Publication of DE60025808D1 publication Critical patent/DE60025808D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE60025808T 1999-02-02 2000-02-02 Verwendung von protein thank, ein tnf homolog, zur hemmung des tumorwachstums Expired - Fee Related DE60025808D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11853199P 1999-02-02 1999-02-02
PCT/US2000/002751 WO2000045836A1 (en) 1999-02-02 2000-02-02 Uses of thank, a tnf homologue that activates apoptosis

Publications (1)

Publication Number Publication Date
DE60025808D1 true DE60025808D1 (de) 2006-04-13

Family

ID=22379181

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60025808T Expired - Fee Related DE60025808D1 (de) 1999-02-02 2000-02-02 Verwendung von protein thank, ein tnf homolog, zur hemmung des tumorwachstums

Country Status (7)

Country Link
US (2) US6475986B1 (de)
EP (1) EP1146894B1 (de)
JP (1) JP2002536338A (de)
AU (1) AU2753500A (de)
CA (1) CA2361617C (de)
DE (1) DE60025808D1 (de)
WO (1) WO2000045836A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
NZ513284A (en) 1999-01-25 2003-10-31 Biogen Inc BAFF blocking agents and their use in the stimulation and inhibition of B-cells and immunoglobulins in immune responses
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
MXPA02001665A (es) 1999-08-17 2003-07-14 Biogen Inc Receptor de baff (bcma) como agente inmunorregulador.
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
ATE329610T1 (de) * 2000-02-16 2006-07-15 Genentech Inc Anti-april antikörper und hybridomazellen
US20040013674A1 (en) * 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
AU2001268427B2 (en) 2000-06-16 2007-03-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
EP2267018A3 (de) * 2000-08-18 2011-04-20 Human Genome Sciences, Inc. Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CN1636067A (zh) * 2001-08-03 2005-07-06 杰南技术公司 TACls和BR3多肽及其用途
AU2003221256A1 (en) * 2002-02-21 2003-09-09 Biogen Idec Ma Inc. Use of bcma as an immunoregulatory agent
WO2004094620A2 (en) 2003-03-28 2004-11-04 Biogen Idec Ma Inc. Truncated baff receptors
US20050095243A1 (en) * 2003-06-05 2005-05-05 Genentech, Inc. Combination therapy for B cell disorders
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
US7811983B2 (en) * 2003-06-11 2010-10-12 The University Of Chicago Increased T-cell tumor infiltration and eradication of metastases by mutant light
EP1641491B1 (de) * 2003-06-11 2008-01-02 University of Chicago Erhöhte t-zell tumor-eindringung durch light- mutanten
WO2005014618A2 (en) * 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
EP1814577B1 (de) 2004-10-13 2014-04-23 The Washington University Verwendung von baff zur behandlung von sepsis
DE602006007323D1 (de) * 2005-01-28 2009-07-30 Biogen Idec Inc VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
WO2006083961A2 (en) * 2005-02-01 2006-08-10 Research Development Foundation Blys fusion proteins for targeting blys receptor and methods for treatment of b-cell proliferative disorders
CA2626082C (en) * 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2629306A1 (en) * 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
WO2008098183A2 (en) * 2007-02-08 2008-08-14 The University Of Chicago Combination therapy for treating cancer
JP2012507299A (ja) * 2008-10-31 2012-03-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｇｈｔ標的分子およびその使用
US20110014190A1 (en) * 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
WO1998018921A1 (en) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
JP2002517977A (ja) * 1997-06-06 2002-06-18 リジェネロン ファーマシューティカルズ，インコーポレイテッド Ｔｎｆリガンドファミリーのｎｔｎ−２メンバー
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
SK3532000A3 (en) * 1997-09-12 2001-12-03 Apotech R & D Sa Dna sequence coding for kay ligand, method for the preparation of kay ligand, pharmaceutical composition containing said ligand and the use thereof
US20010010925A1 (en) * 1997-11-17 2001-08-02 Steven R. Wiley Methods of detecting target nucleic acids of tnf-delta
US7045603B2 (en) 1997-11-24 2006-05-16 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6404770B1 (en) * 1997-12-02 2002-06-11 Yamaha Corporation Data communication interface with adjustable-size buffer
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
AU4986700A (en) 1999-05-06 2000-11-21 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
EP1259544B1 (de) 2000-02-11 2011-08-24 Biogen Idec MA Inc. Heterologes polypeptid der tnf familie

Also Published As

Publication number Publication date
EP1146894A4 (de) 2003-02-26
US20030166546A1 (en) 2003-09-04
WO2000045836A1 (en) 2000-08-10
EP1146894B1 (de) 2006-02-01
US7241576B2 (en) 2007-07-10
US6475986B1 (en) 2002-11-05
CA2361617A1 (en) 2000-08-10
EP1146894A1 (de) 2001-10-24
CA2361617C (en) 2010-08-10
AU2753500A (en) 2000-08-25
JP2002536338A (ja) 2002-10-29

Similar Documents

Publication Publication Date Title
DE60025808D1 (de) Verwendung von protein thank, ein tnf homolog, zur hemmung des tumorwachstums
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE69836991D1 (de) Vierkammer-Herzschrittmachersystem zur Optimierung des Herzzeitvolumens
DE69839211D1 (de) Das tartratsalz eines substituierten dipeptides zur förderung der sekretion von wachstumshormon
PL339463A1 (en) April - novel protein of growth promoting action
DE60130723D1 (de) Implantierbarer Herzschrittmacher zur Optimierung der Reizungseffektivität
DE69713295D1 (de) Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung
DE60034815D1 (de) Ein pyrrolidinacetatderivat zur behandlung von chronischem oder neuropathischem schmerz
DE69829858D1 (de) System zum verankern von gewebe an knochen
NO20003707L (no) FremgangsmÕte for Õ anrike levende for med næringsstoffer essensielle for fiskelarver
DE69830591D1 (de) HEILUNG VON BRUCHVERLETZUNGEN UNTER VERWENDUNG VON PTHrP ANALOGEN
DE69918305D1 (de) Schale zur abgabe von medikamenten
EP1604024A4 (de) Verfahren zur verwendung von wachstumsfaktoren zur behandlung von herzerkrankungen
DE60009327D1 (de) Verbesserte schnittstelle zur verwaltung von verfahrenseichvorrichtungen
ATE280181T1 (de) Künstliche peptide mit oberflächenaktivität und ihre verwendung zur herstellung von künstlichen tensiden
ATE390474T1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
DE60026644D1 (de) Verwendung von Ferulasäure zur Behandlung von Bluthochdruck
DE69933057D1 (de) Analoge des humanen basischen fibroblasten-wachstumsfactors
IT1293170B1 (it) Struttura di contenitore provvisto di mezzi per la somministrazione autoregolata particolarmente di acqua, finalizzato alla coltivazione
ATE363288T1 (de) Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung
DE59704933D1 (de) Verwendung von PHMB zur Behandlung von Tumorerkrankungen
DE50011084D1 (de) Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs
DE69935350D1 (de) Verwendung von pyrethroidverbindungen zur förderung des haarwuchses
DE69825949D1 (de) Programmierbarer Herzschrittmacher zur Stimulation mehrerer Herzbereiche
ATA54498A (de) Begrünungsmatte zur hangbefestigung

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee